Career Path Blog
Blog about career path, career tips and job opportunities

Astellas Pharma Inc. (“Astellas” headquarters: Tokyo President and CEO: Masafumi Nogimori) and AstraZeneca K.K. (headquarters: Tokyo President and CEO: Masuhiro Kato) announced thatSymbicort® Turbuhaler® 30 doses and Symbicort® Turbuhaler® 60 doses (generic name: Budesonide/Formoterol fumarate dihydrate) for the therapy of adult bronchial asthma will be launched on January13, 2010 in Japan.

Symbicort® Turbuhaler® is a twice-every day treatment for adult bronchial asthma combining budesonide, an inhaled corticosteroid (one dose containing 160μg) and formoterol fumarate dihydrate, a rapid and long acting β2 agonist (1 dose containing four.5μg), and the product is administered by an inhaler (Turbuhaler).

Characteristics of Symbicort® Turbuhaler® are as follows:
-The Product alone shows great efficacy in countering each of the causes of bronchial asthma, airway inflammation and airway narrowing
- By administering two medications in one product, in addition to the convenience for controlling bronchial asthma, due to the quickly onset of bronchial dilation impact of formoterol, patients can simply really feel the impact of the remedy. As a result, improvement in adherence (continuation of therapy) can be expected.

Symbicort® Turbuhaler® was listed as a new choice for lengthy-term upkeep remedy on “Asthma Prevention and Management Guideline 2009, Japan” which was revised in October 2009.
The guideline recommends that Symbicort® Turbuhaler® can be used for the treatment from step two to step 4 as the mixture therapy combining an inhaled corticosteroid and a rapid and lengthy-acting β2 agonist.

Symbicort® Turbuhaler® was first approved in Europe in 2000, and is now approved in a lot more than 100 countries and regions. The product will be manufactured and developed by AstraZeneca K.K. and distributed and sold by Astellas Pharma Inc., whilst promotion will be jointly carried out by each businesses (co-promotion).

P.S. Avoid asthma attacks by eating Vitamin C and Vitamin D rich foods and fruits.

source

New inhaler delivers significantly much more drug to the deep lung, regardless of strength of breath Dry Powder Inhaler

Cambridge Consultants and Sun Pharma Advanced Study Organization Ltd develop a high efficiency, simple to use dry powder inhaler

Cambridge Consultants, a leading technology item style and development firm, has created a new high efficiency, effortless to use dry powder inhaler in collaboration with Sun Pharma Advanced Study Firm Ltd (“SPARC”), 1 of India’s leading pharmaceutical study businesses. The inhaler has a uniform delivery profile that ensures the full intended metered dose of the drug is administered to the deep lung, regardless of the strength of the patient’s intake of breath.

The device employs a novel de-agglomeration engine to separate the drug from the lactose ‘carrier’ particles. Based on a highly efficient airway style, the patented drug separation mechanism has effectively completed clinical trials and demonstrated that it is capable of delivering significantly more of the drug to the deep lung than conventional inhalers. In practice, this will minimise side effects from drug develop-up in the back of the throat, reduce non-systemic load and wastage, and means almost 50% much less active drug requirements pre-loading into the device in comparison to a standard inhaler.

This step alter in inhaler technologies is a dependable and straightforward to use device, particularly for patients with impaired lung function or those employing the inhaler during an asthma attack – overcoming any patient concerns about the capacity to use the device efficiently.

In addition to its novel drug delivery mechanism, the device integrates a number of user-friendly style features. These incorporate a numerical dose counter to indicate at a glance how several more doses are left in the inhaler ahead of it runs out, a luminous feature to allow users to uncover the device in the dark and a tiny pop-out ‘braille’ button which activates when there are only a few doses remaining. The device provides audible and tactile feedback to indicate the delivery and completion of user steps. The device also features a exclusive palm-held form, designed to discreetly house the complicated dose carriage and delivery method however stay comfortable to hold and use.

If you have asthma, know the symptoms of heart illness and other inflammatory illnesses so you can treat them early.

The Environmental Protection Agency announced new rules that will need coal-burning energy plants to limit emissions of toxic air pollutants that are recognized to exacerbate asthma. That is great news for the 8 percent of Americans who suffer from the breathing disorder. And according to a new study being presented at this week’s annual meeting of the American Academy of Allergy, Asthma and Immunology, it could lead to fewer rates of other inflammatory diseases. The authors of the study found that individuals with asthma are far more most likely to suffer from cardiovascular disease, diabetes, irritable bowel disease (IBS), and rheumatoid arthritis than folks with healthy lungs.

THE Details: The authors employed data from two,392 men and women enrolled in an asthma study in Rochester, Minnesota, half of whom had asthma and the other half did not. They compared the incidence of irritable bowel illness, rheumatoid arthritis, diabetes, and coronary artery disease amongst those with asthma and those without having, and located that with each and every illness, men and women with asthma had higher rates. The relationship was strongest with coronary artery illness, in which individuals with asthma had a 59 percent higher incidence, and with diabetes, in which men and women with diabetes had a 68 percent higher incidence. Rates of irritable bowel disease and rheumatoid arthritis also elevated in asthma patients, but, says lead author Young J. Juhn, MD, pediatrician at the Mayo Clinic in Rochester, the associations weren’t as strong.

WHAT IT Means: Although it might seem logical to think that an inflammatory condition like asthma would be accompanied by other inflammatory conditions, such as diabetes and cardiovascular disease, Dr. Juhn says his outcomes came as somewhat of a surprise, based on the way our immune systems work. “Our immune systems have something known as T-helper cells. T-helper 1 cells establish pro-inflammatory conditions, such as coronary artery disease, irritable bowel illness, rheumatoid arthritis, and diabetes, whilst T-helper 2 cells are regarded as to play a quite crucial role in determining allergic disorders, such as asthma,” he says. Because our immune systems function to maintain a balance in between the two kinds, he adds, it would stand to reason that men and women with asthma would in fact have lower rates of those diseases. But that’s not what his study located. “At this point, we believe there may possibly be some widespread immune mechanisms underlying this association,” he says, most most likely some thing genetic or environmental.